Docoh
Loading...

HUGE FSD Pharma

Filed: 28 Oct 20, 9:10am

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2020

Commission File Number: 001-39152

FSD PHARMA INC.
(Translation of registrant's name into English)

First Canadian Place
100 King St W, Suite 3400
Toronto, Ontario
M5X 1A4
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [  ]      Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):              

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

INCORPORATION BY REFERENCE

The Registrant's Material Change Report dated October 27, 2020, included as Exhibit 99.1 of this Form 6-K (Commission File No. 001-39152), furnished to the Commission on October 27, 2020, is incorporated by reference into the Registration Statement on Form F-10 (Commission File No. 333-236780) of the Registrant, FSD Pharma Inc.


SIGNATURES

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

FSD Pharma Inc.

 

 

(Registrant)

 

 

 

 

 

 

Date: October 28, 2020

 

By: /s/ Donal Carroll            

 

 

Name: Donal Carroll

 

 

Title:  Chief Financial Officer



EXHIBIT INDEX

Exhibit

Description

 

 

99.1

Material Change Report dated October 27, 2020